The Influence of Treatment With Sofosbuvir/Velpatasvir on Children's Growth-Results of the PANDAA-PED Study.

Maria Pokorska-ŚpiewakEwa TalarekMałgorzata AniszewskaMagdalena PlutaAnna DobrzenieckaMagdalena MarczyńskaGiuseppe Indolfi

Published in: The Pediatric infectious disease journal (2024)

Results of the PANDAA-PED study showed normal growth up to 1 year after successful treatment with SOF/VEL in children 6-18 years of age. Despite the decrease in BMI Z score in boys observed at 12 weeks after treatment, no differences were found between baseline and 1-year posttreatment values. Our observations confirm the long-term safety of the SOF/VEL treatment in children 6-18 years of age.

Keyphrases

young adults
body mass index
hepatitis c virus
physical activity
combination therapy
weight loss
smoking cessation
gestational age